Birincil kaynak kaydı
Karar niteliğindeÖn sonuçlar
Gilead/Merck: ISLEND-1 ve ISLEND-2 Faz 3 üst düzey sonuçları islatravir/lenakapavir için karşılandı
Two Phase 3 trials (ISLEND-1, ISLEND-2) met the primary endpoint of non-inferiority at Week 48 for the once-weekly oral islatravir/lenacapavir regimen versus BIKTARVY or standard-of-care daily ART. The companies plan to file the data with global regulators and present detailed results at a future scientific congress.
Temel olgular
- Bildirildi
- 8 Haz 2026 20:35
- Olay
- Ön sonuçlar
- Yön
- Olumlu
- Şirket
GILDGilead- Varlık
- islatravir/lenacapavir
- Kaynak
- Şirket basın bülteni
- Güvenilirlik
- Kaynaklı
Kaynak alıntısı
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment – Novel Investigational Combination Pairs Merck’s Islatravir, a Next-Generation Nucleoside Analog with Distinct Mechanisms of Action, Including Reverse Transcriptase Translocation Inhibition, with Gilead’s Lenacapavir, a First-in-Class Capsid Inhibitor that Disrupts HIV at Multiple Stages of its Lifecycle – – Islatravir/Lenacapavir has the Potential to be the